FDA Clears $40 Generic HIV Shot, Cutting Access Timeline to 16 Months

Key points

• The FDA approved a generic lenacapavir injection developed by India’s Dr. Reddy’s Laboratories, marking the first affordable version of the drug.
• The generic will cost $40 per person per year in 120 low- and middle-income countries, matching the price of daily oral PrEP.
• The approval process took only 16 months, a record speed compared to the typical decade-long delay for generic antiretrovirals.
• Initial supplies are expected to reach countries like Zambia by World AIDS Day on December 1, 2026.
• The move addresses critical supply shortages, as Gilead Sciences, the original manufacturer, cannot meet global demand alone.

Background

Lenacapavir, branded as Yeztugo by Gilead Sciences, was approved by the FDA in June 2025. It is described as the closest thing to an HIV vaccine, offering near-complete protection with just two injections per year. Prior to this generic approval, access was limited by high costs and insufficient production volumes. In 2025, Gilead granted voluntary licenses to six generic manufacturers to expand access, but supply remained constrained in many regions.

How outlets are covering it

The Independent and Unitaid emphasize the speed of the approval, noting that the 16-month timeline is unprecedented compared to the usual ten-year lag for generic antiretrovirals. AP News highlights the frustration of patients in Uganda and other areas who cannot access the drug due to shortages, despite high demand. ABC News focuses on the convenience of the injection over daily pills, noting that adherence is a major barrier with oral PrEP. However, MSF and other advocates argue that the current licensing agreements exclude countries with high infection rates, such as Brazil, and call for broader access. Unitaid and CHAI stress that while the drug is a milestone, funding and health system readiness are still needed to scale distribution to the 20 million people who need PrEP.

Why it matters

This approval could significantly reduce new HIV infections by making a highly effective prevention tool affordable and accessible in the hardest-hit regions. It represents a major step toward the UN goal of ending the AIDS epidemic by 2030, potentially saving millions of lives and reducing the burden on healthcare systems in low-income countries.

What to watch

Initial shipments of the generic lenacapavir are expected to reach countries like Zambia by the end of 2026, with broader availability in 2027. The Global Fund and US government aim to reach three million people by 2028. However, advocates are pushing for expanded licensing to include countries currently excluded, such as Brazil, and for increased funding to ensure equitable access.